[ad_1]
The drug does not protect against mild and moderate illnesses caused by this variant of the virus.
According to a newspaper report, the vaccine developed by Astrazeneca does not appear to offer complete protection against the coronavirus mutation that was discovered in South Africa and recently spread widely in Tyrol. The drug does not protect against mild and moderate illnesses that are caused by this variant of the virus, reports the “Financial Times,” citing a study to be published Monday.
First 36,000 cans of AstraZeneca in Austria
The British-Swedish vaccine plays a key role in the Austrian vaccination plan. A first delivery with 36,000 cans arrived in Austria on Saturday night and by the end of March it should be 700,000 cans. In view of studies that do not allow to expect total protection against corona diseases, Astrazeneca emphasizes that the vaccine protects 100 percent against “serious diseases, hospitalizations and deaths”.
Proponents of the vaccine point out that it is easier to administer than studies have shown that mRNA vaccines are much more effective and cost much less. The Astrazeneca vaccine is criticized for the study’s carelessness and the lack of reliable data on its effectiveness in the most vulnerable group over 65 years of age. There were also differences of opinion on the fulfillment of supply contracts with the European Union, which had financed the development of the vaccine with large advances.
